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studying the effect(s) of fluoxetine in patients
with a recent stroke: a study protocol for three
multicentre randomised controlled trials
Gillian Mead1, Maree L. Hackett2, Erik Lundström3, Veronica Murray4ˆ, Graeme J. Hankey5 and Martin Dennis1*Abstract
Background: Several small trials have suggested that fluoxetine improves neurological recovery from stroke.
FOCUS, AFFINITY and EFFECTS are a family of investigator-led, multicentre, parallel group, randomised,
placebo-controlled trials that aim to determine whether routine administration of fluoxetine (20 mg daily) for
6 months after acute stroke improves patients’ functional outcome.
Methods/Design: The three trial investigator teams have collaboratively developed a core protocol. Minor
variations have been tailored to the national setting in the UK (FOCUS), Australia and New Zealand (AFFINITY)
and Sweden (EFFECTS). Each trial is run and funded independently and will report its own results. A prospectively
planned individual patient data meta-analysis of all three trials will subsequently provide the most precise estimate
of the overall effect of fluoxetine after stroke and establish whether any effects differ between trials and subgroups
of patients.
The trials include patients ≥18 years old with a clinical diagnosis of stroke, persisting focal neurological deficits at
randomisation between 2 and 15 days after stroke onset. Patients are randomised centrally via web-based
randomisation systems using a common minimisation algorithm. Patients are allocated fluoxetine 20 mg once daily
or matching placebo capsules for 6 months. Our primary outcome measure is the modified Rankin scale (mRS) at
6 months. Secondary outcomes include the Stroke Impact Scale, EuroQol (EQ5D-5 L), the vitality subscale of the
Short-Form 36, diagnosis of depression, adherence to medication, adverse events and resource use. Outcomes are
collected at 6 and 12 months. The methods of collecting these data are tailored to the national setting. If FOCUS,
AFFINITY and EFFECTS combined enrol 6000 participants as planned, they would have 90 % power (alpha 5 %)
to detect a common odds ratio of 1.16, equivalent to a 3.7 % absolute difference in percentage with mRS 0–2
(44.0 % to 47.7 %). This is based on an ordinal analysis of mRS adjusted for baseline variables included in the
minimisation algorithm.
Discussion: If fluoxetine is safe and effective in promoting functional recovery, it could be rapidly, widely and
affordably implemented in routine clinical practice and reduce the burden of disability due to stroke.
Trial registration: FOCUS: ISRCTN83290762 (23/05/2012), AFFINITY: ACTRN12611000774921 (22/07/2011).
EFFECTS: ISRCTN13020412 (19/12/2014).
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The burden of stroke
Each year, stroke affects 16 million people for the first
time and causes about 5.7 million deaths worldwide [1].
About 50 % of survivors will have long-term residual
disability. This places a huge burden on health and social
services and informal carers. Although there is more
that can be done to implement effective treatments such
as thrombolysis and more rapid access to stroke units,
there is still an urgent need to identify new treatments
that might reduce neurological impairments, disability
and dependency. One promising intervention that needs
to be tested is a widely used antidepressant drug, fluoxet-
ine, a selective serotonin reuptake inhibitor (SSRI).
SSRIs
SSRIs have been used in clinical practice since 1988 to
treat mood disorders, particularly depression. They are
sometimes used to manage emotionalism after stroke.
Furthermore, animal studies have shown that fluoxetine
may attenuate post-ischaemic brain injury by facilitating
expression of neuro-protective and regenerative pro-
teins, suppressing post-stroke hyperexcitability in un-
affected brain and reducing inflammation [2, 3]. SSRIs
may also stimulate neuronal generation [4, 5], secretion
of growth factors that augment neuroplasticity [6, 7],
synaptic plasticity [8], expression of brain phosphory-
lated cyclic adenosine monophosphate response element
binding protein [9] and attenuate hypothalamic pituitary
axis overactivity [10], thus reducing cortisol, which is as-
sociated with poorer outcomes post-stroke [11].
A systematic review of SSRIs in animal models of
stroke identified 21 experiments reporting the efficacy of
fluoxetine in 252 animals; neurobehavioural scores im-
proved by 41 % (95 % CI 27–54 %) but there was insuffi-
cient evidence to determine the likely underlying
mechanisms [12].
In healthy humans, functional magnetic resonance im-
aging studies have demonstrated that fluoxetine can
modulate cerebral motor activity [13]. In strokes result-
ing in motor deficits, fluoxetine can cause hyperactiva-
tion in the ipsi-lesional primary motor cortex during a
motor task [14] and a decrease of motor excitability over
the unaffected hemisphere [15].
Promising effect of fluoxetine on stroke recovery in the
fluoxetine for motor recovery after acute ischaemic
stroke (FLAME) trial [16]
The FLAME trial results, presented in October 2010, ig-
nited worldwide interest in the role of fluoxetine for
motor recovery [16]. In this double-blind, placebo-
controlled, multicentre trial 118 patients with ischaemic
stroke and unilateral motor weakness were randomised
to receive fluoxetine 20 mg daily or placebo for 3months. At day 90, the improvement in the Fugl Meyer
motor score from baseline was significantly greater in
the fluoxetine group. Also, the frequency of independent
patients [with a modified Rankin scale (mRS) of 0–2]
was significantly higher in the fluoxetine group (26 % vs.
9 %, p = 0.015) although there were not significant dif-
ferences at other mRS cut-offs.
Cochrane systematic review of SSRIs for stroke recovery
[17]
In a Cochrane systematic review of SSRIs for stroke re-
covery we identified 52 randomised controlled trials of
SSRI versus control (4059 patients), given within the first
year after ischaemic or haemorrhagic stroke, for any in-
dication [17]. Only two trials (n = 223), including
FLAME, reported the mRS as an outcome measure; the
proportion of patients with mRS 0–2 at the end of treat-
ment was 62.5 % in the SSRI group and 55 % in the con-
trol group (absolute difference 7.5 %, 95 % CI: −5.3 to
20.4). Among 22 trials (1310 patients) that reported dis-
ability as an outcome measure, meta-analysis demon-
strated a large effect size of SSRI (SMD 0.92, 95 %
confidence intervals 0.62 to 1.23). The effect size was lar-
ger for patients with depression at recruitment [standar-
dised mean difference (SMD) 1.11, 95 % CI 0.71, 1.51]
than those without (SMD 0.55, 95 % CI 0.27 to 0.84)
(p = 0.03 between groups). The effect size was smaller in
trials at low risk of bias. SSRIs improved several secondary
outcomes (e.g. neurological impairment, depression and
anxiety) at the end of treatment, but there was a non-
significant excess of seizures, gastrointestinal adverse
effects and bleeding. However, the meta-analysis identified
multiple biases in trial design, substantial statistical het-
erogeneity among the trials, wide confidence intervals for
effect estimates and limited data on adverse effects. Only
seven trials followed up patients after treatment had
ended; of these only two (n = 155) provided data on
disability.
Fluoxetine was the most commonly used drug in the
review. However, only 12 fluoxetine trials (n = 682) were
placebo controlled. Of these, six measured the degree of
functional recovery; fluoxetine was associated with less
disability compared with placebo (SMD 0.35, 95 % CI
0.03 to 0.61) at the end of treatment. Although promis-
ing, the data are not sufficiently compelling to prove that
fluoxetine improves functional recovery after stroke and
that any possible benefits are not offset by serious ad-
verse effects.
Why choose fluoxetine to test in a large randomised trial?
We have chosen to evaluate fluoxetine because it is one
of the most widely studied SSRIs. Its safety profile is very
well established, and the drug is well tolerated, in long-
term use, even in older people. There are more trials in
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and in patients with cardiovascular disease, than for
alternatives, such as citalopram [17]. A number of man-
ufacturers produce the drug and the price is low. Lastly,
of all the SSRIs, it has the longest half life, so that gradual
reduction in dose is not required when withdrawing the
drug (which is inevitable in a trial) to reduce the possibil-
ity of an SSRI withdrawal syndrome [18].
What are the potential risks of fluoxetine in stroke?
There are potential risks associated with giving fluoxet-
ine to a wide range of stroke patients. Our systematic
review indicated that SSRIs, compared with placebo or
usual care, were associated with a non-significant ex-
cess of seizures [relative risk (RR) 2.7; 95 % CI 0.6-11.6]
(7 trials, 444 participants), gastrointestinal adverse effects
(RR 1.9; 0.9-3.8) (14 trials, 902 participants) and bleeding
(RR 1.6; 0.2-13) (2 trials, 249 participants) [17]. Cohort
studies, whilst prone to confounding and indication bias,
have also reported that SSRI use is associated with in-
creased risk of seizures, bleeding and hyponatraemia, par-
ticularly during the first 4 weeks of treatment [19–23]. Its
interaction with antiplatelet and anticoagulant medication
might increase bleeding risk. Hence, co-prescription of
fluoxetine with antiplatelet or anticoagulant medications
that are commonly used by stroke patients might increase
bleeding risk in this population of patients. Like other
antidepressants, fluoxetine may lower seizure threshold
and therefore could increase the frequency of post-stroke
seizures. Although evidence on this is conflicting, we are
excluding patients with a history of epileptic seizures [24].
An adverse effect on glycaemic control in diabetics has
been recorded. Hyponatraemia is a recognised adverse ef-
fect and may prove to be more common amongst stroke
patients who may be taking concomitant angiotensin-
converting enzyme inhibitors, diuretics and proton pump
inhibitors. However, reassuringly, fluoxetine has been very
commonly prescribed for several years to patients with
stroke to treat depression and emotionalism without
major problems emerging. Subject to assessment by the
responsible clinician, some stroke patients with severe
renal or hepatic failure may not be able to participate in
the trials.
The need for large randomised trials of fluoxetine in stroke
A cardinal principle of all research should be “trust but
verify”. Given the encouraging data from the FLAME
trial and other smaller studies, there is an urgent need
to carry out randomised trials that have adequate power
to reliably detect clinically important benefits and haz-
ards. Fluoxetine is inexpensive (only about £2.50 per
month in the UK), simple-to-administer and generally
well tolerated. If it proves to be safe in stroke patients
and has an effect on functional recovery after stroke thatis even a fraction of that seen in the FLAME trial it
would be a very worthwhile treatment for patients, their
carers, and health and social services.
The need to identify the patients who might particularly
benefit from treatment
Whilst fluoxetine may improve outcome for the whole
range of stroke patients, it is also plausible given its
diverse pharmacological effects that the balance of risk
and benefit may vary in patients with different types of
stroke. For instance, pre-clinical work has suggested that
motor recovery may be specifically enhanced (see above).
Also, fluoxetine influences bleeding risk, particularly in
those taking antithrombotic medication, so there could be
differences in effectiveness between patients with ischae-
mic (who are taking antithrombotics) and those with
haemorrhagic stroke. Patients with severe stroke associ-
ated with cognitive and communication problems may be
at greater risk of adverse effects because patients are
unable to report early problems but they might also have
more to gain from a treatment that enhances recovery.
Also, those with severe stroke are normally at greater risk
of post-stroke depression (which is associated with stroke
severity) but—as a consequence of their deficits—are at
greater risk that their post-stroke depression is not recog-
nised and so goes untreated [25].
Study objectives
We have collaboratively designed and implemented a
family of three large, investigator-led, government and
charity-funded, multicentre, placebo-controlled rando-
mised trials that together aim to robustly address several
research questions.
Our aims are to determine whether the routine adminis-
tration of fluoxetine 20 mg od started between 2 and 15
days post stroke, and continued for 6 months, improves
recovery and whether any benefits persist after the treat-
ment has stopped until 12 months after the stroke.
Primary research question
Does the routine administration of fluoxetine (20 mg od)
for 6 months after an acute stroke improve patients’ func-
tional status at 6 months?
Secondary research questions
1. If fluoxetine improves functional status at 6 months,
does any improvement in functional status persist
after treatment is stopped?
2. Does fluoxetine influence the secondary outcome
measures (stroke impact, fatigue, mood and quality
of life) at 6 months and 12 months?
3. Does fluoxetine increase the risk of serious
adverse events?
Fig. 1 Patient flow in the FOOD, AFFINITY and EFFECTS trials
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5. Is fluoxetine associated with longer-term survival?
Functional outcome at 6 months post stroke is
strongly associated with long-term survival and so
we wish to determine whether any benefits on
functional outcome would be translated into
longer-term survival.
6. Does the presence or absence of any of the following
factors materially alter the effect of fluoxetine on
our primary outcome?
a. Stroke pathology (i.e. haemorrhagic stroke vs.
ischaemic stroke)
b. Age (age ≤70, >70 years)
c. Stroke severity (predicted probability of a good
outcome vs. poor outcome)
d. Depression at baseline
e. Inability to assess mood because of
communication or cognitive problems
(based on need for proxy consent)
7. In patients with motor deficits at randomisation
does fluoxetine improve motor function?
8. In patients with aphasia at randomisation does
fluoxetine improve communication?
9. Is there a relationship between functional status at 6
months and mood and is this relationship affected
by fluoxetine?
Methods
Design
The FOCUS, AFFINITY and EFFECTS trials are multi-
centre, parallel-group, double-blind, placebo-controlled
trials with broad entry criteria and follow-up to ascertain
the primary and secondary outcomes at about 6 and 12
months (Fig. 1). This section describes the core protocol
that the three trials share and the variations adopted to fa-
cilitate each trial in its national setting. The following de-
scription reflects the versions of the trial protocols in use
on 1 March 2015.
Start-up phases
Each trial has completed a start-up phase to establish
whether the protocol is feasible in each setting and to
establish the trial management teams, IT systems to
manage web-based randomisation, drug allocation, stock
control, follow-up, data collection and verification,
and important aspects of feasibility including recruit-
ment, medication adherence, questionnaire completion
and follow-up rates.
Main phase
The trials are powered to detect differences in a primary
outcome based on an ordinal analysis of the seven-
category modified Rankin scale (mRS 0, 1, 2, 3, 4, 5, 6)
for the entire group [26]. Because it is not feasible toenrol sufficient patients in each trial to reliably detect
small effect sizes that would still be of clinical signifi-
cance we plan to perform an individual patient data
meta-analysis including the data from FOCUS, AFFIN-
ITY and EFFECTS. This will allow us to provide the
most precise estimates of any risks and benefits to detect
a smaller overall effect size than those detectable by the
individual trials and also to determine the effects in
subgroups.
Patient population
Patients will be identified by participating clinicians from
in-patient stroke services and outpatient clinics in the UK
(FOCUS), Australasia and Asia (AFFINITY) and Sweden
(EFFECTS).
Our inclusion criteria are:
 Males and females aged ≥18 years
 A clinical stroke with brain imaging that is compatible
with intracerebral haemorrhage or ischaemic stroke
(including those with normal CT scans)
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15 days after stroke onset
 Persisting focal neurological deficit is present at the
time of randomisation severe enough to warrant
treatment from the patient’s or carer’s perspective.
Our exclusion criteria are:
 Subarachnoid haemorrhage (except where secondary
to a primary intracerebral haemorrhage or enrolling
in AFFINITY)
 Unlikely to be available for follow-up for the next
12 months, e.g. no fixed home address
 Unable to speak English (FOCUS) or Swedish
(EFFECTS) AND no close family member available
to help with follow-up forms
 Other life-threatening illness (e.g. advanced cancer)
that will make 12-month survival unlikely
 History of epileptic seizures
 History of allergy to fluoxetine
 Contraindications to fluoxetine including:
 Hepatic impairment (alanine aminotransferase >3
upper normal limit)
 Renal impairment (creatinine levels >180 micromol/l
and in AFFINITY also eGFR <30 ml/min/1.73 m2)
 Hyponatraemia (sodium < 125 mmol/l) in
AFFINITY
 Pregnant or breast-feeding women of child-bearing
age not taking contraception. Minimum contracep-
tion is an oral contraceptive
 Previous drug overdose or attempted suicide
 Already enrolled into a CTIMP
 Current or recent (within the last month)
depression requiring treatment with an SSRI
antidepressant. AFFINITY also excludes patients
requiring treatment or currently treated with any
antidepressant
 Current use of medications that have a serious
interaction with fluoxetine
 Use of a monoamine oxidase inhibitor (MAOI)
during the last 5 weeks (e.g. phenelzine,
isocarboxacid, tranylcypromine, moclobemide
selegiline and rasagiline)
 Pimozide
 AFFINITY also excludes those taking tramadol
unless the person is willing to stop
 AFFINITY specifically excludes patients with a
diagnosis of bipolar disease and patients receiving
treatment with an antipsychotic medication or
tamoxifen
 EFFECTS excludes patients who are unable to
consent for themselves, FOCUS and AFFINITY
allow consent by a proxy, and AFFINITY allows
waiver of consent in specific circumstances.Co-enrolment
Inclusion in another research study does not automatic-
ally exclude a patient from participating in these trials.
As long as inclusion in the other study would not con-
found the results of the trials or make attribution of
adverse reactions difficult, co-enrolment is permissible.
However, if a participant has already been enrolled into
another CTIMP, they cannot be enrolled into the trials.
If a patient is enrolled into one of the trials, they may
not subsequently be enrolled into another CTIMP. Also,
local researchers must avoid overburdening patients.
Randomisation
Having obtained consent, the randomising person collects
the baseline data (see Table 1) on a randomisation form
and enters these data into a trial-specific computerised
central randomisation service by means of a secure 24/7
Web interface or a telephone call to the trial office during
office hours. After the computer programme has checked
these baseline data for completeness and consistency it
allocates that patient a unique study identification number
and a treatment pack number that corresponds to either
fluoxetine or placebo. The trial-specific system applies a
common minimisation programme to achieve a balance of
four factors:
 Delay since stroke onset (2–8 vs. 9–15 days)
 Predicted 6-month outcome (based on the six
simple variable model [27])
 Presence of a motor deficit [based on the National
Institute of Health Stroke Scale (NIHSS)] [28]
 Presence of aphasia (based on NIHSS)
Following randomisation, the trial co-ordinating centre
(FOCUS, EFFECTS) or randomising centre (AFFINITY)
generates and sends a letter to inform the General Practi-
tioner of the patient’s enrolment in the trial, including a
copy of the consent form, follow-up schedule and advice
about treatment of depression in patients participating in
the trials.
Treatment allocation
The minimisation algorithm randomly allocates the first
patient to a treatment, but allocates each subsequent
patient in a ratio of 1:1 to the treatment that leads to the
least difference between the treatment groups with respect
to the prognostic factors [29]. To ensure that we retain a
random element to treatment allocation, patients are allo-
cated to the group that minimises differences between
groups with a probability of 0.8. The systems contain a list
of treatment codes for each centre and that match the
stock of IMP held at that centre. At the end of the session
each patient is allocated a treatment code that cor-
responds to either an active (fluoxetine 20 mg once daily)
Table 1 Baseline data collected prior to randomisation in the
three trials
Data item FOCUS AFFINITY EFFECTS
Eligibility confirmed + + +
Consent confirmed + + + Patient only
Participant’s names + + +
Date of birth + + +
Gender + + +
Ethnicity + + +
Living arrangements + + +
Employment + + +
Co-morbidities (existing)
• Previous ischaemic
stroke/TIA
+ + +
• Previous intracranial
bleeding
+ + +
• Coronary heart disease + + +
• Current or past depression + + +
• Diabetes + + +
• Gastrointestinal bleeding + + +
• Hyponatraemia + + +
• Fractures + + +
Current medication + + +
NIHSS including
subsections [28]
+ + +
Prior independence 1 Question mRS 1 Question
Ability to walk alone + + +
Ability to lift both arms + + +
Post-stroke disability
(smRSq) [31–33]
+
Patient health questionnaire
(PHQ) [43, 56]
2-Question
version
9-Question
version
2-Question
version
Haemorrhage on brain
imaging?
+ + +
OCSP classification for
ischaemic stroke [57]
+ + +
Modified TOAST
classification [58]
+ + +
Renal and liver function
test results
+
Contact details to facilitate
central follow-up
+ +
Unique identifier to
facilitate central follow-up
+
Mead et al. Trials  (2015) 16:369 Page 6 of 12or placebo treatment pack with a 6-month supply of
capsules.
Patients are prescribed the study medication (20 mg
capsule of fluoxetine or placebo capsule) to be taken
daily at a time that is likely to maximise their adherence,
i.e. linked to an activity of daily living. If the patient isunable to swallow capsules and has an enteral feeding
tube in place then the capsules may be broken open and
the contents put down the tube according to accepted
methods [30].
Blinding
The patient, their families, the healthcare team including
the pharmacist and anyone involved in outpatient
assessments are blinded to the treatment allocation.
Emergency unblinding systems are available for each
trial. The relevant chief investigators will decide on a
case-by-case basis whether unblinding is required to en-
sure patient safety.
Follow-up
Participants are followed up in all three trials at 6 and 12
months to collect the primary and secondary outcomes.
However, the trials vary in the timing, frequency and
method of monitoring the patients’ progress (Table 2).
At early follow-up, during the index admission and in
the first month to identify adverse events, monitor
adherence is carried out by the local centres in all three
trials. However, each trial’s national coordinating centres
follow up the patients at 6 and 12 months with postal
and telephone questionnaires to measure the primary
and secondary outcomes. Data are also collected from
general practitioners and by data linkage to mortality
and hospital admission data in all three trials. The rea-
sons why patients stopped taking the trial medication
will be recorded.
Primary and secondary outcomes
The primary outcome is functional status, measured with
the modified Rankin scale (mRS) [26] at the 6-month
follow-up. We are using the simple modified Rankin scale
questionnaire [31–33] delivered by postal questionnaire,
or via interview over the telephone or face to face to
determine the mRS.
Secondary outcomes
 Survival till the end of the trial. This will be
determined by following patients up for 12 months
through their GPs and telephone and postal
questionnaire and thereafter through linkage to
routine mortality data
 Functional status (mRS) at 12-month follow-up
 Health status with the Stroke Impact Scale (SIS)
(for each of nine domains on which the patient
scores 0–100) [34–36]
 Arm, hand, leg and foot strength
 Hand function
 Mobility
 Communication and understanding
 Memory and thinking
Table 2 Study assessment schedules
Assessment Baseline At discharge 1 Week 4 Weeks 12 Weeks 26 Weeks 30 Weeks 52 Weeks
Consent and randomise x
Contact details x f,e a
Living circumstances x f x e x x
Training (physio, etc.) e e e
10 Outcome-smRSq (mRS) [26, 31–33] a a x x
Depression diagnosis x f,e a x x x
PHQ2 [56] f,e
PHQ9 [43] a a a a
MHI 5 [37–39] f,e f,e
MADRS [40, 41] e e e
Emotionalism e
DSM IV for depression [42] e e e e
SIS [34–36] x x
Fatigue subscale SF36 [44, 45] x e x x
Cognition (TICSm) [46] a a
Cognition (MoCA) [47] e e
EQ5D-5 L [48] e e x x
EQD thermometer a a
SF12 [59] a
Adverse events f,e e a,e e x x
Adherence to IMP f e a,e e x
All medications x f a x a
Retrieve residual capsules (pill count) e x
Physical therapy received e e
Resource use over 12 months x
f = FOCUS, a = AFFINITY, e = EFFECTS, x = completed in all three trials
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 Daily activities
 Participation in work, leisure and social activities
 Overall rating of recovery
 Adverse events/outcomes
 Depression. Although the SIS includes a domain
reflecting mood, in the trials we are collecting
additional information on the diagnosis and
treatment of depression during follow-up.
Participants are asked if they have been diagnosed
with depression since their last assessment, whether
this has been treated and whether they have been
started on an antidepressant medication. Mood is
assessed during follow-up in FOCUS and EFFECTS
with the Mental Health Inventory 5 [37–39]. In
addition EFFECTS uses the Montgomery-Åsberg
Depression Rating Scale (MADRS) and patients
scoring high have a diagnosis of depression confirmed
based on the DSM-IV criteria [40–42]. The PHQ-9
[43] is administered at baseline (covering the 4 weeks
before stroke), 1, 3, 6 and 12 months in AFFINITY Recurrent stroke including ischaemic and
haemorrhagic strokes
 Acute coronary syndromes
 Epileptic seizures
 Episodes of hyponatraemia (<125 mmol/l)
 Upper gastrointestinal bleeding
 Other major bleeds (lower GI, extracranial,
intracranial but extracerebral)
 Poorly controlled diabetes including
hyperglycaemia (>22 mmol/l) and
hypoglycaemia
 Falls resulting in injury
 New fractures
 Attempted suicide/self harm
 Death
 Fatigue (Vitality subscale of SF36) [44, 45]
 Cognition—the SIS, which incorporates an
assessment of memory and thinking, is used for all
three trials. In AFFINITY cognition during follow-up
is assessed with the Modified Telephone Interview
for Cognitive Status (TICSm) [46]. EFFECTS assess
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(MoCA) [47]
 Health-related quality of life measured with the
five-level Euroqol 5D (EQ5D-5 L) to generate
utilities [48]
Each trial is collecting data about resource use over
the first 12 months to enable us to carry out health
economic analyses.
Provisional analysis plan
A detailed analysis plan for each trial, and for an indi-
vidual patient data meta-analysis, will be developed and
reported by the chief investigators and an independent
statistician prior to the database being locked at the end
of follow-up for final analysis.
The primary analyses will retain patients in their
original assigned treatment groups. We will use ordinal
regression to compare functional status (mRS scores) at
the 6-month follow-up, adjusted for those factors included
in our minimisation algorithm [49].
In secondary analyses we will compare the two treat-
ment groups with respect to the following outcomes
at 6 and 12 months:
 Survival will be analysed with the Cox proportional
hazards model adjusting for the factors included in
the minimisation algorithm
There is evidence that functional outcome at 6 months
post stroke is strongly associated with long-term survival
[50]. Therefore, if fluoxetine treatment is associated with
improvements in functional status at 6 months it would
be important to establish whether this translates into
longer survival.
Subgroup analyses
The functional status (mRS) at 6 months will be compared
with ordinal regression in the following subgroups:
 Age (≤70, > 70 years)
 Baseline probability of a good outcome on mRS
calculated with the six simple variable model
[27]—to see whether effects remain constant across
the range of stroke severities (<0.15 vs. 0.15-1
probability of being alive and independent at
6 months)
 Ischaemic vs. haemorrhagic stroke
 Patients who were unable to consent for themselves
since this subgroup will allow us to answer the
question whether routine use of fluoxetine is likely
to benefit patients in whom a formal assessment of
mood is impossible because of communication and
cognitive problems.In addition we are particularly interested to know
whether the effect of treatment on neurological function
is modified by specific neurological deficits present at
baseline. Because patients may have a combination of
neurological deficits, individual patients may appear in
more than one subgroup
 Subgroup 1: Patients with a motor deficit affecting
the face/arm or leg
 Relevant outcomes: SIS-Strength, mobility,
hand/arm function
 Subgroup 2: Patients with aphasia Relevant outcomes: SIS-communicationThe functional status (mRS) at 12 months will be
compared with that at 6 months to establish whether
any benefits observed at 6 months are maintained. If no
difference is observed in the functional status between
the treatment groups at 6 months, then secondary
analyses will aim to establish whether there are differ-
ences with respect to the secondary outcomes, and if so
whether these are maintained at 12 months.
We will also perform analyses of potential mediating
factors, e.g. the role of depression. We will seek to
answer the question whether any benefits are mediated
by improvement in mood (based on MHI5, MADRS or
PHQ9) and also whether any apparent loss of benefits in
mRS or SIS between 6 months to 12 months is because
of a deterioration in mood.
We envisage that levels of missing data in the primary
outcome will be exceedingly low from previous experi-
ence of acquiring the mRS by postal and telephone ques-
tionnaire [51–55] and the primary analysis will be a
complete case analysis. If we see higher levels of missing
data than expected, we will use a suitable analysis, based
on the likely missing data mechanism. We will consider
whether to extend missing data methods to secondary
outcomes at a blinded review of the Statistical Analysis
Plan immediately before the database lock.
Economic analyses
Each trial will develop a detailed health economic
analysis plan before completion of data collection to
determine the cost-effectiveness of fluoxetine in the
trial setting.
Sample size/power calculations
FOCUS, AFFINITY and EFFECTS are planning to enrol
at least 3000, 1600 and 1500 patients respectively. Table 3
shows the effect sizes [expressed as a common odds
ratio (COR)]. These numbers would provide 90 % power
with an alpha of 0.05. These estimates are based on the
distribution of outcomes in the seven categories of the
mRS (0–6) (observed in both treatment groups combined
Table 3 Sample size calculations derived from an ordinal regression and based on 90 % power and alpha 0.05
Trial Sample size Common odds ratio % mRS 0–2 fluoxetine % mRS 0–2 placebo Absolute % improvement in mRS 0-2
EFFECTS 1500 1.35 49.5 42.1 7.4
AFFINITY 1600 1.34 49.4 42.2 7.2
FOCUS 3000 1.23 48.4 43.2 5.2
Pooled 4500 1.19 48.0 43.6 4.4
Pooled 6000 1.16 47.7 44.0 3.7
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6 months in the FOCUS trial).
If FOCUS, AFFINITY and EFFECTS combined enrol
6000, we would have 90 % power (alpha 5 %) to detect a
COR of 1.16, equivalent to a 3.7 % absolute difference in
percentage with mRS 0–2 (44.0 % to 47.7 %).
The trial steering committees (TSC) will regularly
review the target sample size and adjust this based on
accruing blinded data on
 the enrolment into specific pre-specified subgroups
 completeness of follow-up
 distribution of mRS categories in the population of
enrolled subjects (i.e. both treatment groups
combined), overall and in specific patient categories
(e.g. those with motor deficits, aphasia, etc.)
For example, if the distribution of mRS is different
from that anticipated, then the sample size might need
to be increased to maintain the power of the trial to
detect the specified effect size. This approach has the
advantage that such sample size adjustments can be
made without reference to the accumulating blinded
data and avoid the need for conditional power calcula-
tions, which can be unreliable.
Study funding
The three trials are funded by grants from charitable orga-
nisations and government funding bodies (see acknowl-
edgements for details). They do not receive any funding
from the pharmaceutical industry.
Ethics approvals
Each trial has received approval for its protocol and trial
materials from the relevant local ethics committees
and regulatory authorities in their respective countries
[FOCUS: Scotland A Research Ethics Committee (for UK)
(21/12/2011); AFFINITY: Western Australia, Royal Perth
Hospital Human Research Ethics Committee (HREC) (24/
02/2012), New South Wales, Victoria & Queensland,
Western Sydney Local Health District HREC (30/04/
2013), South Adelaide Clinical HREC (01/09/2014), New
Zealand, Central Health and Disability Ethics Committee
(17/04/2014)]. EFFECTS: Stockholm Ethics Committee
(30/09/2013). No centres can start recruitment until theyhave received relevant ethics and regulatory approvals.
Informed consent is obtained before the patient is enrolled
except where it has been waived. Consent procedures had
to comply with national requirements, so that in FOCUS
and AFFINITY approval was obtained for consent by
either the patient or proxy, AFFINITY also has approval
for waiver of consent, whilst in EFFECTS patients have to
be capable of consenting for themselves. The intensity and
methods of monitoring were agreed between trial investi-
gators and the relevant organisation in each country.
Organisation
Each trial has established its own Trial Steering Com-
mittee (TSC) to oversee the conduct and progress of
the trial. Each trial has its own independent Data Moni-
toring Committee (DMC) to oversee the safety of partici-
pants in the trial. During recruitment, interim analyses of
the baseline and follow-up data will be supplied, in strict
confidence, to the chairmen of the data-monitoring com-
mittees, along with any other analyses that the committees
may request. In the light of these analyses, the data-
monitoring committee will advise the chairmen of the
Trial steering committees whether, in their view, the ran-
domised comparisons have provided (1) 'proof beyond
reasonable doubt' that for all, or some, the treatment is
clearly indicated or clearly contra-indicated and (2)
evidence that might reasonably be expected to materially
influence future patient management. Following a report
from the DMC, the steering committees will decide
whether to modify entry to the study (or seek extra data).
Unless this happens, however, the TSC, the collaborators
and central administrative staff will remain ignorant of the
interim results.
The terms of reference of the DMCs specify that any
of the chairmen should confer with the chairmen of the
DMCs of the other trials if they have concerns about the
accruing data. The chairmen may elect to share blinded
or unblinded reports and to request combined analyses
of accruing data in the three trials.
The FOCUS trial is coordinated from the Edinburgh
Clinical Trials Unit (ECTU) (Neurosciences Division)
and sponsored by ACCORD (a joint organisation be-
tween University of Edinburgh and NHS Lothian). The
AFFINITY trial is coordinated from the Stroke Research
Unit in Perth (School of Medicine and Pharmacology,
Mead et al. Trials  (2015) 16:369 Page 10 of 12University of Western Australia, and Sir Charles Gairdner
Hospital, Health Department of Western Australia) and
the Neurological & Mental Health Division, George
Institute for Global Health, in Sydney, Australia. The
EFFECTS trial is coordinated from the Karolinska Institutet
in Stockholm but its randomisation and data storage are
hosted by the ECTU in Edinburgh.
Discussion
The investigators of these three trials agreed to a collab-
orative approach including adhering to a common core
protocol and combining their results to allow a prospect-
ive individual patient data meta-analysis. We judged that a
larger number of participants would be required to answer
our secondary research questions than could be recruited
in any trial within a reasonable time period if based in one
country. Also, we were keen to have sufficient power to
ensure we detected even a modest overall effect, since this
would still have important implications for patients, their
families, and health and social services. The degree of col-
laboration is illustrated by the fact that the co-chief inves-
tigators of each trial participate in each of the three trial
steering committees and have, where allowed, been named
as co-applicants on each of the funding applications. This
means that each of us has an interest in each of the three
trials succeeding.
An alternative strategy that we considered was to
establish a single international trial. However, we decided
that our chosen strategy has several advantages.
We are able to vary trial procedures to fit local condi-
tions. For instance, in the UK, the FOCUS trial is supported
by a well-organised network of principal investigators and
research staff in local centres funded by the National
Institute of Health Research. In Australia and Sweden
the individual trialists have to identify the local support
networks. Regulations vary between countries with re-
spect to whether proxy consent is acceptable and how
patient identifiable data can be shared between centres
and coordinating centres, which influences the feasibility
of centralised follow-up and the intensity of monitoring
required by regulators.
Ideally, the three trials would have collected identical
data items at the same time points. Since the vast major-
ity of data items are common to all three trials our ap-
proach did allow for some variation. For instance the
PHQ9 was favoured in Australasia whilst the MHI5 was
favoured in the UK and the MADRS in Sweden. These
small variations should not preclude a valid combined
analysis. Most importantly the eligibility criteria, method
of randomisation, interventions and principal outcome
measures were almost identical.
Our model allows us to confirm the results of one trial
in another two providing valuable evidence of external
validity. It will also allow us to explore any heterogeneityin trial results that may reflect the settings in which each
trial was carried out. For instance, the intensity of back-
ground physical therapies, adherence to the trial drug,
duration of hospitalisation and costs of delivering hos-
pital and social services vary between countries and may
alter the effectiveness or cost effectiveness of fluoxetine
in treating stroke patients.
Our model negates the need to gain approvals for
transporting supplies of active drug and placebo across
international jurisdictions. It allowed the investigators in
each country to apply for, and secure, funding for their
own trial, which has provided more resources than were
likely to be available from any one funding agency. Gov-
ernmental and charitable funding agencies often put
limits on how much of their grant funding can be spent
abroad. Our approach also encouraged local ownership
of the trial, which will hopefully facilitate faster recruit-
ment and more complete follow-up.
Our DMCs are also collaborating to maximise patient
safety. If safety concerns are raised as data accrue within
one trial, the DMC charters encourage the chairs to share
data for confirmation of a problem or for reassurance.
We urgently need new treatments to reduce the bur-
den of disability after stroke. These three multicentre,
investigator-led, charity- and government-funded rando-
mised trials will determine whether the routine adminis-
tration of fluoxetine 20 mg daily (for 6 months) in
stroke survivors between 2 and 15 days after stroke im-
proves recovery at 6 months, whether any benefits per-
sist after fluoxetine has been discontinued and whether
there are benefits in specific subgroups. If fluoxetine is
effective, the results of the trial could be rapidly imple-
mented throughout the world at very little cost to health
services.
Trials status
All three trials are actively recruiting. FOCUS recruited
its first patient on 10 September 2012, AFFINITY on 11
January 2013 and EFFECTS on 20 October 2014. Our
target is to complete recruitment in all three trials by
2018.
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